Table 1.

Current or recently completed clinical trials testing therapies for chronic hepatitis delta (CHD) infection. Abbreviations: Immunomod: immunomodulatory mechanism; NAP: Nucleic Acid Polymer; CYP3A4, Cytochrome P450 3A4; NA, not applicable. Eiger: Eiger Biopharmaceuticals.

Compound(s) Tested/Class	Class	Phase of Trial (n)	Sponsor	Status as of this Writing	Publication/Observations
(1) EBP921	prenylation inhibitor	Phase 1 (8)	Eiger	Unknown	NA
(1) Lonafarnib	(1) farnesyl transferase inhibitor	Phase 2 (40)	Eiger	Recruiting	NA
(2) Ritonavir	(2) inhibitor of HIV protease and CYP3A4
(1) Lonafarnib	(1) see above	Phase 2 (21)	Eiger	Recruitiung	Ritonavir + lonafarnib: 3.2 log10 decline in viral load was observed at week 8 of treatment
(2) Ritonavir	(2) see above
(3) Peginterferon	(3) immunomod
(1) Peginterferon alpha2A	(1) immunomod	Phase 2 (13)	NIDDK	Completed (results published)	Heller, Rotman et al. (2014) [44]
(1) REP 2139-Ca	(1) NAP:blocks HBV subviral particle formation	Phase 2 (12)	REPLIcor	Ongoing (not recruiting) mid 2016 estimated completion	~6 log10 decline HDV RNA, standalone REP2139-Ca
(2) Pegasys®	(2) immunomod
(1) Ribavirin	(1) nucleoside inhibitor	Phase 4 (20)	National Taiwan Univer. Hospital	Unknown	NA
(2) Pegylated Interferon Alfa-2B	(2) immunomod
(1) Peginterferon alpha2A	(1) immunomod	Observational	Hoffman LaRoche	Ongoing, not recruiting	NA
(1) Peginterferon alpha2A	(1) immunomod	Phase 2 (70)	HepNet Study house; Hoffman La-Roche; Gilead	Ongoing, not recruiting	NA
(2) Tenofovir	(2) nucleotide analog
(1) Lonafarnib	(1) farnesyl transferase inhibitor	Phase 2 (14)	NIDDK	Completed	NA
(1) Peginterferon alpha2A	(1) immunomod	Phase 3 (50)	Hoffman-La Roche	Ongoing, not recruiting	NA
(2) Tenofovir	(2) nucleotide analog
(1) Myrcludex B	(1) hepatocyte entry	Phase 2a (24)	Hepatera	Completed	Myr standalone: >1Log10 HDV RNA decline and ALT normalization in 4 subjects at week 24
2) PEG-IFNa	(2) immunomod